Trial reportCardiovascular diabetology2013
Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women.
Trial report in Cardiovascular diabetology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 71 citations in OpenAlex.
- Exercise increases serum endostatin levels in female and male patients with diabetes and controls.Cardiovascular diabetology · 2014Trial
- Association between lipid accumulation product and cognitive impairment: a community-based 4-year prospective cohort study.Aging clinical and experimental research · 2025Article
- Differences in Inflammatory Pathways Between Dutch South Asians vs Dutch Europids With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2023Article
- Gender Differences and Cardiometabolic Risk: The Importance of the Risk Factors.International journal of molecular sciences · 2023Review
- Increased LDL-cholesterol level is associated with deterioration of renal function in males.Clinical kidney journal · 2022Article
- Influence of Gender in Diabetes Mellitus and Its Complication.International journal of molecular sciences · 2022Review
- Sex Differences in Cardiovascular Prevention in Type 2: Diabetes in a Real-World Practice Database.Journal of clinical medicine · 2022Article
- Morphological alteration of the pancreatic islet in ovariectomized rats fed a high-fat high-fructose diet.Histochemistry and cell biology · 2022Article
- The Relationship between Cancer and Paraoxonase 1.Antioxidants (Basel, Switzerland) · 2022Review
- Update on Management of Cardiovascular Diseases in Women.Journal of clinical medicine · 2022Review
- The influence of inflammation on cardiovascular disease in women.Frontiers in global women's health · 2022Review
- Trends of Sex Differences in Clinical Outcomes After Myocardial Infarction in the United States.CJC open · 2021Article
- Anthropometric Measurements, Metabolic Profile and Physical Fitness in a Sample of Spanish Women with Type 2 Diabetes.International journal of environmental research and public health · 2021Article
- Possible Gender Influence in the Mechanisms Underlying the Oxidative Stress, Inflammatory Response, and the Metabolic Alterations in Patients with Obesity and/or Type 2 Diabetes.Antioxidants (Basel, Switzerland) · 2021Review
- Sex Differences in Lipid Profile across the Life Span in Patients with Type 2 Diabetes: A Primary Care-Based Study.Journal of clinical medicine · 2021Article
- Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis.Cardiovascular diabetology · 2021Observational
- Sex Difference Impacts on the Relationship between Paraoxonase-1 (PON1) and Type 2 Diabetes.Antioxidants (Basel, Switzerland) · 2020Article
- Correlates of pentraxin 3 serum concentration in men and women with type 2 diabetes.Innate immunity · 2020Article
- Could remnant-like particle cholesterol become a risk factor in diabetic menopausal women with coronary artery disease? A cross-sectional study of single academic center in China.Lipids in health and disease · 2020Article
- Sex difference: an important issue to consider in epidemiological and clinical studies dealing with serum paraoxonase-1.Journal of clinical biochemistry and nutrition · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study is to evaluate the effect of gender and menopause in cardiometabolic risk in a type 2 diabetes mellitus (T2DM) population, based on classical and non-traditional markers.
methodsSeventy four volunteers and 110 T2DM patients were enrolled in the study. Anthropometric data, blood pressure, body mass index (BMI), waist circumference (WC) and the following serum markers were analyzed: glucose, Total-c, TGs, LDL-c, Oxidized-LDL, total HDL-c and large and small HDL-c subpopulations, paraoxonase 1 activity, hsCRP, uric acid, TNF-α, adiponectin and VEGF.
resultsNon-diabetic women, compared to men, presented lower glycemia, WC, small HDL-c, uric acid, TNF-α and increased large HDL-c. Diabetes abrogates the protective effect of female gender, since diabetic women showed increased BMI, WC, small HDL-c, VEGF, uric acid, TNF-α and hsCRP, as well as reduced adiponectin, when compared with non-diabetic. In diabetic females, but not in males, WC is directly and significantly associated with TNF-α, VEGF, hsCRP and uric acid; TNF-α is directly associated with VEGF and hsCRP, and inversely with adiponectin. Postmenopausal females presented a worsen cardiometabolic profile, viewed by the increased WC, small HDL-c, VEGF, uric acid, TNF-α and hsCRP. In this population, WC is directly and significantly associated with TNF-α, VEGF, hsCRP; TNF-α is directly associated with VEGF; and uric acid is inversely associated with large HDL-c and hsCRP with adiponectin, also inversely.
conclusionsDiabetes abrogates the protective effect of gender on non-diabetic women, and postmenopausal diabetic females presented worsen cardiometabolic risk, including a more atherogenic lipid sketch and a pro-inflammatory and pro-angiogenic profile. The classical cardiovascular risk factors (CVRFs) fail to completely explain these differences, which are better clarified using "non-traditional" factors, such as HDL-c subpopulations, rather than total HDL-c content, and markers of inflammation and angiogenesis, namely TNF-α, hsCRP, uric acid and VEGF. Multi-therapeutic intervention, directed to obesity, atherogenic lipid particles and inflammatory mediators is advisory in order to efficiently prevent the serious diabetic cardiovascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.